Evidence map›Paper›PMID 35772820›Full record

ArticleBMJ open2022

Health system costs of a breast cancer early diagnosis programme in a rural district of Rwanda: a retrospective, cross-sectional economic analysis.

Rashidah Nambaziira, Lysa Carolle Niteka, Jean Marie Vianney Dusengimana, John Ruhumuriza, Kayleigh Pavitra Bhangdia, Jean Claude Mugunga, Marie Louise Uwineza, Vestine Rugema, Parsa Erfani, Cyprien Shyirambere and 3 more

Abstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rashidah NambaziiraUniversity of Global Health Equity, Butaro, Rwanda.
Lysa Carolle NitekaUniversity of Global Health Equity, Butaro, Rwanda.
Jean Marie Vianney DusengimanaPartners In Health, Butaro, Rwanda.
John RuhumurizaPartners In Health, Butaro, Rwanda.
Kayleigh Pavitra BhangdiaHarvard T H Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0003-4235-0685
Jean Claude MugungaMonitoring, Evaluation and Quality Improvement, Partners In Health, Arlington, Massachusetts, USA.
Marie Louise UwinezaRwanda Ministry of Health, Butaro, Rwanda.
Vestine RugemaRwanda Ministry of Health, Butaro, Rwanda.
Parsa ErfaniHarvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-5738-0556
Cyprien ShyiramberePartners In Health, Butaro, Rwanda.
Lawrence N ShulmanUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Melany RabideauUniversity of Global Health Equity, Butaro, Rwanda.
Lydia E PaceBrigham and Women's Hospital, Boston, Massachusetts, USA lpace@bwh.harvard.edu.ORCID 0000-0002-5378-0296

Funding

Evaluating breast cancer care in rural RwandaK07CA215819 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI PACE, LYDIA · 2018 to 2023
$1.0M
NCI NIH HHS K07 CA215819
6 · The paper itself

Abstract

objectivesThis study aimed to quantify the health system cost of the first 2 years of a Breast Cancer Early Detection (BCED) programme in a rural district in Rwanda. We also aimed to estimate the cost of implementing the programme in other districts with different referral pathways and identify opportunities for enhanced cost efficiency.

designRetrospective, cross-sectional analysis using time-driven activity-based costing, based on timed patient clinical encounters, retrospective patient data and unit costs of resources abstracted from administrative and finance records.

settingThe BCED programme focused on timely evaluation of individuals with breast symptoms. The study evaluated the health system cost of the BCED programme at seven health centres (HCs) in Burera district and Butaro Cancer Centre of Excellence (BCCOE) at Butaro District Hospital. OUTCOME MEASURES: Health system costs per patient visit and cost per cancer diagnosed were quantified. Total start-up and recurring operational costs were also estimated, as well as health system costs of different scale-up adaptations in other districts.

resultsOne-time start-up costswere US$36 917, recurring operational costswere US$67 711 and clinical costswere US$14 824 over 2 years. Clinical breast examinations (CBE) at HCs cost US$3.27/visit. At BCCOE, CBE-only visits cost US$13.47/visit, CBE/ultrasound US$14.79/visit and CBE/ultrasound/biopsy/pathology US$147.81/visit. Overall, clinical cost per breast cancer diagnosed was US$1482. Clinicalcost drivers were personnel at HCs (55%) and biopsy/pathology supplies at BCCOE (46%). In other districts, patients experience a longer breast evaluation pathway, adding about US$14.00/patient; this could be decreased if ultrasound services were decentralised.

conclusionClinical costs associated with BCED services at HCs were modest, similar to other general outpatient services. The BCED programme's start-up and operational costs were high but could be reduced by using local trainers and virtual mentorship. In other districts, decentralising ultrasound and/or biopsies to district hospitals could reduce costs.

Indexed as

Breast NeoplasmsEarly Detection of CancerCross-Sectional StudiesFemaleHumansRetrospective StudiesRwandabreast tumourshealth economicsprimary care

Identifiers

PMID35772820
PMCPMC9247687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.